ArticleeLife2019
Gene activation by a CRISPR-assisted
Article in eLife, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 31 citations in OpenAlex.
- Epigenome Engineering Using dCas Systems for Biomedical Applications and Biotechnology: Current Achievements, Opportunities and Challenges.International journal of molecular sciences · 2025Review
- A platform to deliver single and bi-specific Cas9/guide RNA to perturb genes in vitro and in vivo.Molecular therapy : the journal of the American Society of Gene Therapy · 2024Article
- Characterization of transcriptional enhancers in the chicken genome using CRISPR-mediated activation.Frontiers in genome editing · 2023Article
- A synthetic transcription platform for programmable gene expression in mammalian cells.Nature communications · 2022Article
- The Human Tissue-Engineered Cornea (hTEC): Recent Progress.International journal of molecular sciences · 2021Review
- CRISPR technologies for precise epigenome editing.Nature cell biology · 2021Review
- Various Aspects of a Gene Editing System-CRISPR-Cas9.International journal of molecular sciences · 2020Review
- Engineering cell fate: Applying synthetic biology to cellular reprogramming.Current opinion in systems biology · 2020Article
- Understanding the Plant-microbe Interactions in CRISPR/CAS9 Era: Indeed a Sprinting Start in Marathon.Current genomics · 2020Review
- Recent advances of genome editing and related technologies in China.Gene therapy · 2020Review
- Long Non-coding RNAs in the Regulation of the Immune Response and Trained Immunity.Frontiers in genetics · 2020Article
- Dead Cas Systems: Types, Principles, and Applications.International journal of molecular sciences · 2019Review
- Perturbing Enhancer Activity in Cancer Therapy.Cancers · 2019Review
- Off-target effects of CRISPRa on interleukin-6 expression.PloS one · 2019Article
- Human sensory neurons derived from pluripotent stem cells for disease modelling and personalized medicine.Neurobiology of pain (Cambridge, Mass.)Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
The deactivated CRISPR/Cas9 (dCas9) is now the most widely used gene activator. However, current dCas9-based gene activators are still limited by their unsatisfactory activity. In this study, we developed a new strategy, the CRISPR-assisted
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.